Seyed Alireza Javadinia/LinkedIn
May 17, 2025, 07:23
Seyed Alireza Javadinia: Findings from ADAPTcycle Trial at ESMO Breast 2025
Seyed Alireza Javadinia, Vice President for Research and Technology, Assistant Professor and Radiation Oncologist at Sabzevar University of Medical Sciences, shared a post on LinkedIn:
“At ESMO Breast 2025, the ADAPT cycle phase III trial (Abstract 189O) revealed that neoadjuvant ribociclib plus endocrine therapy achieves pathological complete response (pCR) rates (5.7%) comparable to chemotherapy (7.1%) in early-stage ER+/HER2– breast cancer (OR 0.79, 95% CI 0.38–1.66, p=0.542). Nodal involvement was a key predictor of pCR, suggesting that clinical and biological factors can guide treatment decisions.
Prof. Christos Sotiriou notes that these similar pCR rates in lower-risk patients indicate ribociclib could potentially replace chemotherapy in select cases, pending further survival data. These findings highlight the importance of personalized risk assessment in optimizing therapy for breast cancer.”
Seyed Alireza Javadinia presented new data from the ADAPT cycle phase III trial showing ribociclib plus endocrine therapy may offer a non-chemotherapy path for some ER+/HER2– breast cancer patients, depending on nodal involvement and other clinical factors.
More posts featuring Seyed Alireza Javadinia.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 1, 2025, 16:47
Jul 1, 2025, 16:16
Jul 1, 2025, 10:32
Jul 1, 2025, 09:57